TABLE 1.
Study participant characteristics by compliance status to split-dosing recommendations (N = 462)
| Patient characteristics | Split-dosing recommendation | Total | P value* | |
|---|---|---|---|---|
| Compliant (n = 391) | Noncompliant (n = 71) | |||
| Demographic | ||||
| Age, y, mean (SD) | 56.5 (6.7) | 58.2 (7.8) | 56.8 (6.9) | .07 |
| Male | 192 (49.2) | 39 (56.5) | 231 (50.3) | .26 |
| White | 345 (88.5) | 53 (76.8) | 398 (86.7) | .009 |
| Hispanic or Latino | 5 (1.3) | 6 (8.7) | 11 (2.4) | <.001 |
| Married | 288 (74.4) | 41 (59.4) | 329 (72.2) | .01 |
| BMI, kg/m2, mean (SD) | 28.9 (5.8) | 28.7 (5.7) | 28.9 (5.8) | .85 |
| High school education or less | 61 (15.7) | 13 (18.8) | 74 (16.2) | .51 |
| Full-time employment | 223 (57.3) | 40 (58.0) | 263 (57.4) | .92 |
| On Medicare | 55 (14.5) | 15 (22.1) | 70 (15.6) | .11 |
| On Medicaid or no insurance | 17 (4.5) | 3 (4.3) | 20 (4.4) | .95 |
| ≤$75,000 annual income | 145 (39.1) | 39 (58.2) | 184 (42.0) | .004 |
| Health-related measures | ||||
| Very good or excellent health | 260 (67.0) | 43 (62.3) | 303 (66.3) | .45 |
| History of stroke | 9 (2.3) | 3 (4.4) | 12 (2.6) | .33 |
| History of cirrhosis | 3 (0.9) | 1 (1.5) | 4 (0.9) | .58 |
| On prescription pain pills | 28 (7.2) | 3 (4.4) | 31 (6.8) | .39 |
| On tricyclic antidepressant† | 6 (1.6) | 0 (0) | 6 (1.3) | .30 |
| History of constipation | 73 (18.9) | 10 (14.5) | 83 (18.2) | .39 |
| Never nauseous | 65 (16.6) | 13 (18.3) | 78 (16.9) | .73 |
All values are number (percentage) of those split-dose compliant or split-dose noncompliant, unless otherwise specified. The total number of patients for each characteristic may not add to total (N = 462) because of missing data.
SD, Standard deviation; BMI, body mass index.
From testing differences in the distribution of the patient characteristics between patients compliant and noncompliant with split-dose guidelines; based on a t test for continuous variables and χ2 test for categorical variables. No adjustments for multiple testing were done as the tests were not meant to be inferential, but to identify variables that are potentially associated with compliance to split-dose preparation.
Taking Tofranil, Mallinckrodt Pharmaceuticals, Hazelwood, MO, (imipramine hydrochloride), Elavil, AstraZeneca, London, UK, (amitriptyline), Norpramin, Sanofi Aventis, Paris, France, (desipramine hydrochloride), Sinequan, Pfizer, New York, NY, (doxepin hydrochloride), or Pamelor, Mallinckrodt Pharmaceuticals, Hazelwood, MO, (nortriptyline hydrochloride).